CLSDQ — Clearside Biomedical, Share News
0.000.00%
Last trade - 00:00- $1.31m
- $55.68m
- $1.66m
Clearside rises on positive data from early-stage eye disorder drug trial
Brief: Clearside Biomedical Positive Oasis And Extension Study Data Presented At The Retina Society 56Th Annual Scientific Meeting
Brief: Clearside Biomedical Announces Advancement Of Xipere® In Asia-Pacific For Treatment Of Uveitic Macular Edema
Brief: Clearside Biomedical Got Letter From Nasdaq That Listing Of Co's Common Stock Was Not In Compliance With Nasdaq Listing Rule
Brief: Clearside Biomedical Q2 EPS USD -0.15
Clearside Biomedical Inc reports results for the quarter ended in June - Earnings Summary
Clearside Biomedical Inc expected to post a loss of 14 cents a share - Earnings Preview
Brief: Clearside Biomedical Says Suprachoroidal Injection Of CLS-AX Resulted In Favorable Safety Data, Durability, Biologic Effect Over 6 Months
Brief: Clearside Biomedical Announces Enrollment Of Multiple Participants In Odyssey Phase 2B Clinical Trial Of Cls-Ax In Wet AMD
Brief: Clearside Biomedical Asia-Pacific Partner Arctic Vision Announces Acceptance In Australia Of New Drug Application For Suprachoroidal Use Of Arcatus
U.S. STOCKS ON THE MOVE-Lands' End, Energy sector
U.S. STOCKS ON THE MOVE-Biogen, NetApp, LyondellBasell
Clearside rises on starting enrollment in eye-drug trial
Brief: Clearside Biomedical Opens Enrollment In Odyssey Phase 2B Clinical Trial Of Cls-Ax (Axitinib Injectable Suspension) In Wet AMD
Brief: Clearside Biomedical Inc Files For Mixed Shelf Of Up To $150 Million – SEC Filing
Brief: Clearside Biomedical Inc - Entered Into Controlled Equity Offeringsm Sales Agreement With Cantor Fitzgerald
Clearside Biomedical Inc reports results for the quarter ended in March - Earnings Summary
Brief: Clearside Biomedical Announces Q1 2023 Financial Results, Provides Corporate Update
Clearside Biomedical Inc expected to post a loss of 14 cents a share - Earnings Preview